Compare FVRR & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FVRR | LRMR |
|---|---|---|
| Founded | 2010 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.6M | 253.5M |
| IPO Year | 2019 | 2014 |
| Metric | FVRR | LRMR |
|---|---|---|
| Price | $7.69 | $3.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $9.42 | ★ $14.20 |
| AVG Volume (30 Days) | 1.0M | ★ 1.3M |
| Earning Date | 10-29-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.57 | $1.92 |
| 52 Week High | $22.17 | $6.42 |
| Indicator | FVRR | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 38.56 | 62.96 |
| Support Level | N/A | $2.89 |
| Resistance Level | $9.07 | $4.25 |
| Average True Range (ATR) | 0.40 | 0.28 |
| MACD | -0.06 | 0.11 |
| Stochastic Oscillator | 7.82 | 86.70 |
Fiverr International Ltd operates a online marketplace that enables sellers to offer digital services and buyers to purchase them The Company's platform features an extensive catalog of digital services that spans over hundreds of categories. Buyers can purchase digital services ranging from simple services such as logo design and blog post writing, to complex services such as video creation, website development and social media marketing. Also, the Company offers value-added services including subscription products, advertising solutions and financial tools designed to support marketplace users and enhance their business activities. The company generates maximum of its revenue from USA.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.